BioGenes Establishes Distribution Network for Generic HCP Assay in Major Markets

BioGenes GmbH has announced that it has signed long-term agreements with distributors in USA and Canada, India, Japan and Middle/South America to offer its enhanced generic HCP assay CHO|360-HCP ELISA within their respective territories. Europe and the rest of world (ROW) will be served by BioGenes directly.

CHO|360-HCP ELISA greatly improves the detection of HCPs in CHO cells by employing differently prepared host cell protein antigens and antibodies from two species. CHO|360-HCP ELISA allows users for the first time to easily choose the antibodies that work best for a specific process.

Dagmar Schwertner, Director of Marketing at BioGenes stated: “We are excited to partner with these premier distributors who will introduce CHO|360-HCP ELISA to their esteemed customer base. The distribution agreements will help leverage BioGenes’ sales and marketing capabilities to establish CHO|360-HCP ELISA as the preferred generic assay for HCP detection in CHO cells. BioGenes will be working closely with its distributors to ensure a high standard of service.”